Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH3A1 | P30838 | 4/20 | 0.68 |
| ▸ | HTT | P42858 | 3/20 | 0.68 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.68 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | GAA | P10253 | 3/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.60 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3471718 | 0.87 | MET (0.70) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL19911385 | 0.85 | ALDH1A1 (0.67) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL19911406 | 0.85 | ALOX5 (0.60) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL422055 | 0.83 | ALDH3A1 (0.77) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL12271942 | 0.81 | ALDH1A1 (0.51) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL3472185 | 0.81 | ALOX5 (1.00) | ALDH3A1HTTL3MBTL1POLBALOX5 | |
| SCHEMBL3470648 | 0.81 | ALOX5 (0.75) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL32679275 | 0.81 | ALDH3A1 (0.73) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL8329551 | 0.81 | ALDH3A1 (1.00) | ALDH3A1HTTNOD1L3MBTL1POLB | |
| SCHEMBL7366346 | 0.79 | KMT2A (1.00) | ALDH3A1HTTNOD1L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021509-A1 | Phosphate transport inhibitors | JOZEFIAK THOMAS H | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021509-A1 | Phosphate transport inhibitors | SLC34A2, SLC34A1, SLC20A1 | ALDH3A1 1297/4885HTT 2299/4885NOD1 583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.